» Articles » PMID: 28130224

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer

Abstract

In this study, we used a bioinformatic approach to identify genes whose expression is dysregulated in human prostate cancers. One of the most dramatically downregulated genes identified encodes CYP27A1, an enzyme involved in regulating cellular cholesterol homeostasis. Importantly, lower CYP27A1 transcript levels were associated with shorter disease-free survival and higher tumor grade. Loss of CYP27A1 in prostate cancer was confirmed at the protein level by immunostaining for CYP27A1 in annotated tissue microarrays. Restoration of CYP27A1 expression in cells where its gene was silenced attenuated their growth and in tumor xenografts. Studies performed revealed that treatment of prostate cancer cells with 27-hydroxycholesterol (27HC), an enzymatic product of CYP27A1, reduced cellular cholesterol content in prostate cancer cell lines by inhibiting the activation of sterol regulatory-element binding protein 2 and downregulating low-density lipoprotein receptor expression. Our findings suggest that CYP27A1 is a critical cellular cholesterol sensor in prostate cells and that dysregulation of the CYP27A1/27HC axis contributes significantly to prostate cancer pathogenesis. .

Citing Articles

Drug Repurposing for Cancer Treatment: A Comprehensive Review.

Al Khzem A, Gomaa M, Alturki M, Tawfeeq N, Sarafroz M, Alonaizi S Int J Mol Sci. 2024; 25(22).

PMID: 39596504 PMC: 11595001. DOI: 10.3390/ijms252212441.


Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.


Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells.

Xiong X, Zhang S, Zhu W, Du J, Liao X, Hu S Oncogene. 2024; 43(47):3456-3468.

PMID: 39369166 DOI: 10.1038/s41388-024-03181-3.


Association between the metabolic score for insulin resistance and prostate cancer: a cross-sectional study in Xinjiang.

Wang J, Apizi A, Tao N, An H PeerJ. 2024; 12:e17827.

PMID: 39076779 PMC: 11285359. DOI: 10.7717/peerj.17827.


Cholesterol neutralized vemurafenib treatment by promoting melanoma stem-like cells via its metabolite 27-hydroxycholesterol.

Wang X, Zhong F, Chen T, Wang H, Wang W, Jin H Cell Mol Life Sci. 2024; 81(1):226.

PMID: 38775844 PMC: 11111659. DOI: 10.1007/s00018-024-05267-3.


References
1.
Bjarnadottir O, Romero Q, Bendahl P, Jirstrom K, Ryden L, Loman N . Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013; 138(2):499-508. DOI: 10.1007/s10549-013-2473-6. View

2.
Yupeng L, Yuxue Z, Pengfei L, Cheng C, YaShuang Z, Dapeng L . Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies. Cancer Epidemiol Biomarkers Prev. 2015; 24(7):1086-93. DOI: 10.1158/1055-9965.EPI-14-1329. View

3.
Sood A, Saxena R, Groth J, Desouki M, Cheewakriangkrai C, Rodabaugh K . Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol. 2007; 38(11):1628-38. PMC: 2121591. DOI: 10.1016/j.humpath.2007.03.010. View

4.
Mondul A, Weinstein S, Virtamo J, Albanes D . Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011; 22(11):1545-52. PMC: 3500884. DOI: 10.1007/s10552-011-9831-7. View

5.
Umetani M, Domoto H, Gormley A, Yuhanna I, Cummins C, Javitt N . 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007; 13(10):1185-92. DOI: 10.1038/nm1641. View